|
|
|
Insider
Information: |
Maraganore John |
Relationship: |
Director |
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
263,534 |
|
Indirect Shares
|
6,153,633 |
|
|
Direct
Value |
$35,156,399 |
|
|
Indirect Value
|
$15,907,580 |
|
|
Total
Shares |
6,417,167 |
|
|
Total
Value |
$51,063,979 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Alnylam Pharmaceuticals Inc |
ALNY |
Chief Executive Office... |
2021-12-22 |
227,663 |
2021-12-22 |
3,133 |
Premium* |
|
Regulus Therapeutics Inc. |
RGLS |
Director, 10% Owner |
2012-10-10 |
0 |
2012-10-10 |
6,150,500 |
Premium* |
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2022-05-20 |
30,028 |
|
0 |
Premium* |
|
Bluebird Bio, Inc. |
BLUE |
Director |
2017-09-14 |
5,843 |
2014-07-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
AGIO |
Agios Pharmaceuticals Inc |
Director |
|
2022-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,585 |
30,028 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-12-22 |
4 |
D |
$186.02 |
$1,254,077 |
D/D |
(6,636) |
227,663 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
14,167 |
234,299 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-12-10 |
4 |
OE |
$42.22 |
$399,829 |
D/D |
5,367 |
220,132 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-11-12 |
4 |
AS |
$170.36 |
$5,827,801 |
D/D |
(33,978) |
214,765 |
0 |
% |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-11-12 |
4 |
OE |
$7.10 |
$241,244 |
D/D |
33,978 |
248,743 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-08-13 |
4 |
OE |
$7.10 |
$241,251 |
D/D |
33,979 |
248,744 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-08-13 |
4 |
AS |
$198.02 |
$6,788,196 |
D/D |
(33,979) |
214,765 |
0 |
% |
|
AGIO |
Agios Pharmaceuticals Inc |
Director |
|
2021-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,686 |
28,443 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-05-13 |
4 |
AS |
$128.30 |
$4,443,725 |
D/D |
(33,979) |
214,765 |
0 |
% |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-05-13 |
4 |
OE |
$7.10 |
$241,251 |
D/D |
33,979 |
248,744 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-04-20 |
4 |
D |
$131.75 |
$989,822 |
D/D |
(7,507) |
214,765 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
16,236 |
222,272 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-02-25 |
4 |
OE |
$7.10 |
$241,251 |
D/D |
33,979 |
240,015 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-02-25 |
4 |
AS |
$143.88 |
$5,005,421 |
D/D |
(33,979) |
206,036 |
0 |
% |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-02-12 |
4 |
D |
$151.94 |
$890,917 |
D/D |
(5,719) |
206,036 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2021-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
14,166 |
211,755 |
0 |
- |
|
AGIO |
Agios Pharmaceuticals Inc |
Director |
|
2021-02-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,415 |
26,757 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2020-11-19 |
4 |
AS |
$123.55 |
$4,319,025 |
D/D |
(34,765) |
197,589 |
0 |
% |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2020-11-19 |
4 |
OE |
$9.14 |
$317,752 |
D/D |
34,765 |
232,354 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2020-08-20 |
4 |
AS |
$135.09 |
$4,732,542 |
D/D |
(34,765) |
197,589 |
0 |
% |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2020-08-20 |
4 |
OE |
$9.14 |
$317,752 |
D/D |
34,765 |
232,354 |
0 |
- |
|
AGIO |
Agios Pharmaceuticals Inc |
Director |
|
2020-05-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,878 |
30,172 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2020-05-20 |
4 |
AS |
$142.51 |
$4,978,983 |
D/D |
(34,765) |
197,589 |
0 |
% |
|
ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
|
2020-05-20 |
4 |
OE |
$9.14 |
$317,752 |
D/D |
34,765 |
232,354 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|